Items tagged with Research and development
A proposed novel approach to TB drug financing (post)
MANILA — Global health experts will be discussing a novel approach to bring better tuberculosis drugs to the market on Sunday, the eve of the 72nd World Health Assembly.
Smarter research & development to tackle global health priorities (post)
Today, May 15, WHO’s new Science Division launched an online resource to guide the development of new health products for which there are limited markets or incentives for research and development. An essential tool for realizing universal health coverage, the Health Product Profile Directory aims to promote research and development for products to combat neglected diseases and threats to global health, including antimicrobial resistance and diseases with pandemic potential.
Future of drug pricing resolution hangs in balance at World Health Assembly (post)
23 May: The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise text.
World Health Assembly approves milestone resolution on price transparency (post)
28 May 2019: The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor.
How to fix the medical R&D model (post)
Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs for Neglected Diseases initiative, Treatment Action Campaign, Treatment Action Group, The International Union Against Tuberculosis and Lung Disease (The Union), and the Mexican National Institute of Health Sciences and Nutrition (National Institute Salvador Zubirán). Here, Rahman shares highlights from the panel on why the medical research and development (R&D) model needs to be ‘fixed’, as well as ways to go about fixing it, including greater transparency, new incentives for investment in R&D that are alternatives to intellectual property, and increased NGO and community participation throughout the research and development process.
Johnson & Johnson commits $500 million investment over four years to help end the epidemics of HIV and TB (post)
Johnson & Johnson announced it has committed to ensuring more than $500 million dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and TB by 2030.
50th Union World Conference on Lung Health: NIH announces $30 million for research to spur TB vaccine development (post)
HYDERABAD, INDIA – The National Institute of Allergy and Infectious Diseases will dedicate $30 million in new funding to accelerate development of new vaccines against tuberculosis.
Industry urges more government action on antibiotic development (post)
The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released today (January 16).
CGD experts discuss MVAC blueprint to create market for new TB drugs (post)
Center for Global Development (CGD): A Final MVAC Blueprint — and the Start of an R&D Revolution?
The European Investment Bank provides €30 million loan to accelerate TB vaccine development (post)
The European Investment Bank (EIB) agreed a €30 million loan with Vakzine Projekt Management GmbH (VPM), the German subsidiary of Serum Institute of India Pvt. Ltd. The loan will help VPM to perform the priMe trial. The priMe project contains a multicentre phase III double-blind, randomised, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to the baccille Calmette–Guérin (BCG) vaccine. Vaccine research and development for the project will be carried out by VPM and the clinical trials will be scaled up in several high-burden sub-Saharan African countries.
Page 12 of 28 · Total posts: 0
←First 11 12 13 Last→